Ozempic: contraindications and effectiveness

What is Ozempic?

Ozempic® (semaglutide) is a GLP-1 (glucagon-like peptide-1) receptor agonist approved for the treatment of type 2 diabetes mellitus.

A separate formulation of semaglutide (Wegovy®) is approved for the treatment of obesity.

The medication is administered subcutaneously once weekly.

Mechanism of Action

Semaglutide:

• enhances glucose-dependent insulin secretion;

• reduces glucagon secretion;

• delays gastric emptying;

• decreases appetite via central satiety mechanisms;

• promotes weight loss.

The delay in gastric emptying explains most gastrointestinal adverse effects.

Indications

Ozempic (according to prescribing information)

Type 2 diabetes:

• inadequate glycemic control;

• in combination with other glucose-lowering agents;

• in patients with high cardiovascular risk.

Semaglutide for obesity (Wegovy)

• BMI ≥ 30 kg/m²
  or

• BMI ≥ 27 kg/m² + metabolic comorbidities (diabetes, hypertension, etc.)

Proven Efficacy

Glycemic Control

According to SUSTAIN trials:

• significant reduction in HbA1c;

• reduction in cardiovascular events in high-risk patients.

Weight Loss

In STEP trials:

• average weight reduction of ~15% at therapeutic doses;

• effect maintained during treatment;

• partial weight regain after discontinuation.

Side Effects

Most common (especially at initiation):

• nausea

• vomiting

• bloating

• constipation

• diarrhea

• heartburn

• early satiety

Less common:

• gastroparesis

• pancreatitis (rare; association debated)

• gallstone disease (more frequent with rapid weight loss)

Most adverse effects are:

• dose-dependent;

• reduced with gradual dose titration.

Contraindications

• Medullary thyroid carcinoma (or family history)

• Multiple endocrine neoplasia type 2 (MEN2)

• Pregnancy

• Severe gastroparesis

• Hypersensitivity

Use with caution in:

• chronic pancreatitis

• significant gastrointestinal symptoms

Semaglutide and Gastrointestinal Effects

From a gastroenterology perspective:

• delayed gastric emptying may worsen dyspepsia;

• possible exacerbation of GERD;

• possible worsening of IBS symptoms in sensitive patients;

• persistent severe nausea requires therapy reassessment.

Prescription in patients with active GI complaints requires careful risk evaluation.

Can It Be Used “Just for Weight Loss”?

Key point:

Semaglutide is a medication, not a cosmetic tool.

Prescription must consider:

• BMI;

• metabolic profile;

• comorbidities;

• risk–benefit balance.

Without lifestyle modification, long-term effectiveness is limited.

Frequently Asked Questions

Does weight return after discontinuation?

Yes, partially, if dietary and behavioral habits are not changed.

Is lifelong therapy required?

The decision is individualized, as in any chronic metabolic condition.

Does it cause cancer?

There is no evidence of increased cancer risk in humans. The warning relates to medullary thyroid carcinoma based on animal studies.

When to See a Doctor

• presence of type 2 diabetes;

• obesity with metabolic complications;

• elevated ALT/AST and suspected MASLD;

• significant GI side effects;

• pregnancy planning.

Conclusion

Semaglutide:

✔ effective for diabetes and obesity management
✔ reduces cardiovascular risk
✔ leads to significant weight loss

However:

⚠ requires medical supervision
⚠ has gastrointestinal side effects
⚠ does not replace lifestyle modification